Dyne Therapeutics (DYN) Current Leases (2021 - 2026)
Dyne Therapeutics (DYN) posted quarterly Current Leases of $5.4 million for Q2 2026, up 7.28% year-over-year from $5.0 million in Q2 2025, and up 6.62% quarter-over-quarter from $5.0 million in Q1 2026.
Dyne Therapeutics (DYN) Current Leases (2021 - 2026) Analysis & Trends
Dyne Therapeutics (DYN) has reported Current Leases for 6 consecutive years, with $5.4 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Current Leases rose 7.28% year-over-year to $5.4 million; the TTM figure through Jun 2026 stood at $5.4 million (up 7.28% YoY), while the FY2025 annual figure was $5.0 million, up 2.99% from the prior year.
- Current Leases advanced to $5.4 million in Q2 2026 per DYN's latest filing, from $5.0 million in the prior quarter.
- Across five years, Current Leases topped out at $5.5 million in Q2 2022 and bottomed at $4.6 million in Q3 2022.
- Historically, Current Leases has averaged $4.9 million across 5 years, with a median of $4.8 million in 2024.
- Annual changes were most pronounced in 2022 — Current Leases climbed 18.42% — and 2023, when it dropped 14.14%.
- Dyne Therapeutics' Current Leases stood at $4.6 million in 2022, then rose by 2.39% to $4.7 million in 2023, then advanced by 2.75% to $4.8 million in 2024, then gained by 2.99% to $5.0 million in 2025, then gained by 7.43% to $5.4 million in 2026.
- Business Quant data shows DYN's Current Leases at $5.4 million in Q2 2026, $5.0 million in Q1 2026, and $5.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 11.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 16.75 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 21.95 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 2.24 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 45.93 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.27 Mn |
| 10 | Dyne Therapeutics | 4.26 Bn | 4.26 Bn | - | 5.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.37 Mn |
| Mar 31, 2026 | 5.03 Mn |
| Dec 31, 2025 | 5.00 Mn |
| Sep 30, 2025 | 5.04 Mn |
| Jun 30, 2025 | 5.00 Mn |
| Mar 31, 2025 | 5.11 Mn |
| Dec 31, 2024 | 4.85 Mn |
| Sep 30, 2024 | 4.81 Mn |
| Jun 30, 2024 | 4.78 Mn |
| Mar 31, 2024 | 4.76 Mn |
| Dec 31, 2023 | 4.72 Mn |
| Sep 30, 2023 | 4.71 Mn |
| Jun 30, 2023 | 4.71 Mn |
| Mar 31, 2023 | 4.64 Mn |
| Dec 31, 2022 | 4.61 Mn |
| Sep 30, 2022 | 4.58 Mn |
| Jun 30, 2022 | 5.49 Mn |
| Mar 31, 2022 | 4.71 Mn |
| Dec 31, 2021 | 3.89 Mn |
| Sep 30, 2021 | 4.59 Mn |